How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

244 results for

Emergency Pediatric Dosing 12-14 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Perampanel 12 or 16 mg/day Pediatric participants, ranging from 1 month to less than 24 months of age, will receive a target dose of perampanel 12 mg/day (non-enzyme-inducing antiepileptic drug [non-EIAED] participants) or 16 mg/day (EIAED participants) administered as an oral suspension once a day for up to 24 weeks. Drug: perampanel oral suspension Other (...) to less than 24 months of age, with epilepsy. Condition or disease Intervention/treatment Phase Epilepsy Drug: perampanel Phase 2 Detailed Description: This is a multicenter, open-label study comprised of pretreatment, treatment (core study), and extension phases that is designed to evaluate the PK of an oral suspension of perampanel (target dose of 12 milligrams per day [mg /day] for non-enzyme-inducing antiepileptic drug [non-EIAED] or 16 mg/day for EIAED) when given as an adjunctive therapy

2016 Clinical Trials

42. Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises

-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02573714 Recruitment Status : Recruiting First Posted : October 12, 2015 Last Update Posted : March 14, 2019 (...) ) First Posted: October 12, 2015 Last Update Posted: March 14, 2019 Last Verified: March 2019 Keywords provided by Cameroon Baptist Convention Health: Ketamine Intranasal Pain crisis Vasoocclusive Pain Sickle cell disease Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Ketamine Analgesics Sensory System Agents Peripheral Nervous System Agents

2015 Clinical Trials

43. Pediatric Supraventricular Tachycardia

):303-10. By | 2016-12-14T12:56:45-04:00 September 15th, 2015 | | Share this post About the Author: Brad Sobolewski, MD, MEd is an Associate Professor of Pediatric Emergency Medicine and an Assistant Director for the Pediatric Residency Training Program at Cincinnati Children's Hospital Medical Center. He is on Twitter @PEMTweets and authors the Pediatric Emergency Medicine site PEMBlog. All views are strictly my own and not official medical advice. Related Posts March 12th, 2019 | May 15th, 2018 (...) features, response to treatment, and long-term follow-up in 217 patients. J Pediatr. 1981;98(6):875-82. Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr. 1996;129(3):324-38. Spencer B, Chacko J, Sallee D. The 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiac care: an overview of the changes to pediatric basic and advanced life support. Crit Care Nurs Clin North Am. 2011;23(2

2015 PEM Blog

44. A Phase I Bioequivalence Study of TAK-536 Pediatric Formulation

Description Go to Brief Summary: The purpose of this study is to evaluate the bioequivalence of a single oral dose of 2 different drug forms of TAK-536 pediatric formulation and a single oral dose of TAK-536 commercial tablet in healthy Japanese adult male participants. Condition or disease Intervention/treatment Phase Japanese Healthy Adult Males Drug: TAK-536 Tablet Drug: TAK-536 Dry Syrup Formulation Drug: TAK-536 Ganule Formulation Phase 1 Detailed Description: This study was designed to evaluate (...) the bioequivalence of a single oral dose of 2 different drug forms of TAK-536 pediatric formulation (dry syrup, granules) and a single oral dose of TAK-536 commercial tablet by using open-label, 2 × 2 crossover design. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 52 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized, Open-label, 2×2

2015 Clinical Trials

45. Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders

Oral Solution in Pediatric Participants With Treatment-Resistant Seizure Disorders Actual Study Start Date : April 13, 2015 Actual Primary Completion Date : May 9, 2016 Actual Study Completion Date : May 9, 2016 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Low Dose Cannabidiol Oral Solution [10 mg/kg/day] Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing (...) : June 23, 2017 Sponsor: INSYS Therapeutics Inc Information provided by (Responsible Party): INSYS Therapeutics Inc Study Details Study Description Go to Brief Summary: This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion. Participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant seizures, and satisfy all inclusion

2014 Clinical Trials

46. Premedication by Midazolam for Emergency Surgery

consumption of hypnotics and opioids [ Time Frame: at anesthesia induction up to 10 minutes ] Cumulative dose of hypnotics and opioids reduced to dose per kilogram Comfort induction [ Time Frame: at anesthesia induction ] rated from 1 for deep discomfort to 5 for good comfort Intubation score [ Time Frame: after intubation ] Rated from 1 bed conditions for intubation to 5 for excellent conditions Adverse midazolam effects [ Time Frame: baseline up to the end of support in recovery room ] assessed (...) Premedication by Midazolam for Emergency Surgery Premedication by Midazolam for Emergency Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Premedication by Midazolam for Emergency Surgery The safety

2014 Clinical Trials

47. Pediatrics, Dehydration (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvODAxMDEyLXRyZWF0bWVudA== processing > Pediatric Dehydration Treatment & Management Updated: Nov 12, 2018 Author: Alex Koyfman, MD; Chief Editor: Muhammad Waseem, MBBS, MS, FAAP, FACEP, FAHA Share Email Print Feedback Close Sections Sections Pediatric Dehydration Treatment Approach Considerations Address emergent airway, breathing, and circulatory problems first. Obtain intravenous access, and give a 20 mL/kg isotonic fluid bolus (Ringer lactate or normal saline) to children with severe volume depletion. This should (...) dose is 0.25 g/kg IV (2.5 mL/kg of 10% dextrose or 1 mL/kg of 25% dextrose) with reassessment of glucose level after administration of dextrose. Once vital sign abnormalities are corrected, initiate maintenance fluid therapy plus additional fluid to make up for any continued losses. Daily requirements for maintenance fluids can be approximated as follows: If the patient weighs less than 10 kg, give 100 mL/kg/d If the patient weighs less than 20 kg, give 1000 mL/d plus 50 mL/kg/d for each kilogram

2014 eMedicine Emergency Medicine

48. Pediatrics, Diabetic Ketoacidosis (Treatment)

. 2008 Jan. 36(1):110-2. . Bismuth E, Laffel L. Can we prevent diabetic ketoacidosis in children?. Pediatr Diabetes . 2007 Oct. 8 Suppl 6:24-33. . Bonadio W. Pediatric diabetic ketoacidosis: an outpatient perspective on evaluation and management. Pediatr Emerg Med Pract . 2013 Mar. 10(3):1-13; quiz 14. . Cardella F. Insulin therapy during diabetic ketoacidosis in children. Acta Biomed Ateneo Parmense . 2005. 76 Suppl 3:49-54. . Cody D. Infant and toddler diabetes. Arch Dis Child . 2007 Aug. 92(8):716 (...) ketoacidosis, fluid therapy, and cerebral injury: the design of a factorial randomized controlled trial. Pediatr Diabetes . 2013 Sep. 14(6):435-46. . . Glaser NS, Wootton-Gorges SL, Buonocore MH, et al. Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis. Pediatr Diabetes . 2006 Apr. 7(2):75-80. . Green SM, Rothrock SG, Ho JD, et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. Ann Emerg Med . 1998 Jan. 31(1):41-8. . Hanas R

2014 eMedicine Emergency Medicine

49. Pediatrics, Sedation (Follow-up)

seconds). Its duration of action is 1-3 minutes, allowing swift emergence and recovery. Preliminary pediatric studies indicate that propofol is efficacious in terms of providing sedation and is easy to use. Monitored anesthesia care (MAC) sedation dosing is 0.5-1 mg/kg by IV push, infused over 2 minutes initially. Maintenance dosing is 0.5-1 mg/kg IV every 3-5 minutes as needed or, alternatively, 50-150 µg/kg/min by continuous IV infusion. Initially, propofol was used as an induction agent in general (...) as appropriate for his or her age, without assistance The child should be able to ingest and retain oral fluids Some agents are associated with specific aftercare needs. For example, ketamine may cause ataxia for 12-24 hours, and the child’s activities should be restricted during this period to prevent further injury. Previous References Sacchetti A. Baren J. Carraccio C. Total Procedural Requirement as Indication for Emergency Sedation. Pediatr Emerg Care . 2010. 26:209-211. . Coté CJ, Wilson S, AMERICAN

2014 eMedicine Emergency Medicine

50. Pediatrics, Sedation (Diagnosis)

seconds). Its duration of action is 1-3 minutes, allowing swift emergence and recovery. Preliminary pediatric studies indicate that propofol is efficacious in terms of providing sedation and is easy to use. Monitored anesthesia care (MAC) sedation dosing is 0.5-1 mg/kg by IV push, infused over 2 minutes initially. Maintenance dosing is 0.5-1 mg/kg IV every 3-5 minutes as needed or, alternatively, 50-150 µg/kg/min by continuous IV infusion. Initially, propofol was used as an induction agent in general (...) as appropriate for his or her age, without assistance The child should be able to ingest and retain oral fluids Some agents are associated with specific aftercare needs. For example, ketamine may cause ataxia for 12-24 hours, and the child’s activities should be restricted during this period to prevent further injury. Previous References Sacchetti A. Baren J. Carraccio C. Total Procedural Requirement as Indication for Emergency Sedation. Pediatr Emerg Care . 2010. 26:209-211. . Coté CJ, Wilson S, AMERICAN

2014 eMedicine Emergency Medicine

51. Pediatrics, Sedation (Treatment)

seconds). Its duration of action is 1-3 minutes, allowing swift emergence and recovery. Preliminary pediatric studies indicate that propofol is efficacious in terms of providing sedation and is easy to use. Monitored anesthesia care (MAC) sedation dosing is 0.5-1 mg/kg by IV push, infused over 2 minutes initially. Maintenance dosing is 0.5-1 mg/kg IV every 3-5 minutes as needed or, alternatively, 50-150 µg/kg/min by continuous IV infusion. Initially, propofol was used as an induction agent in general (...) as appropriate for his or her age, without assistance The child should be able to ingest and retain oral fluids Some agents are associated with specific aftercare needs. For example, ketamine may cause ataxia for 12-24 hours, and the child’s activities should be restricted during this period to prevent further injury. Previous References Sacchetti A. Baren J. Carraccio C. Total Procedural Requirement as Indication for Emergency Sedation. Pediatr Emerg Care . 2010. 26:209-211. . Coté CJ, Wilson S, AMERICAN

2014 eMedicine Emergency Medicine

52. Pediatrics, Sedation (Overview)

seconds). Its duration of action is 1-3 minutes, allowing swift emergence and recovery. Preliminary pediatric studies indicate that propofol is efficacious in terms of providing sedation and is easy to use. Monitored anesthesia care (MAC) sedation dosing is 0.5-1 mg/kg by IV push, infused over 2 minutes initially. Maintenance dosing is 0.5-1 mg/kg IV every 3-5 minutes as needed or, alternatively, 50-150 µg/kg/min by continuous IV infusion. Initially, propofol was used as an induction agent in general (...) as appropriate for his or her age, without assistance The child should be able to ingest and retain oral fluids Some agents are associated with specific aftercare needs. For example, ketamine may cause ataxia for 12-24 hours, and the child’s activities should be restricted during this period to prevent further injury. Previous References Sacchetti A. Baren J. Carraccio C. Total Procedural Requirement as Indication for Emergency Sedation. Pediatr Emerg Care . 2010. 26:209-211. . Coté CJ, Wilson S, AMERICAN

2014 eMedicine Emergency Medicine

53. Pediatrics, Diabetic Ketoacidosis (Follow-up)

. 2008 Jan. 36(1):110-2. . Bismuth E, Laffel L. Can we prevent diabetic ketoacidosis in children?. Pediatr Diabetes . 2007 Oct. 8 Suppl 6:24-33. . Bonadio W. Pediatric diabetic ketoacidosis: an outpatient perspective on evaluation and management. Pediatr Emerg Med Pract . 2013 Mar. 10(3):1-13; quiz 14. . Cardella F. Insulin therapy during diabetic ketoacidosis in children. Acta Biomed Ateneo Parmense . 2005. 76 Suppl 3:49-54. . Cody D. Infant and toddler diabetes. Arch Dis Child . 2007 Aug. 92(8):716 (...) ketoacidosis, fluid therapy, and cerebral injury: the design of a factorial randomized controlled trial. Pediatr Diabetes . 2013 Sep. 14(6):435-46. . . Glaser NS, Wootton-Gorges SL, Buonocore MH, et al. Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis. Pediatr Diabetes . 2006 Apr. 7(2):75-80. . Green SM, Rothrock SG, Ho JD, et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. Ann Emerg Med . 1998 Jan. 31(1):41-8. . Hanas R

2014 eMedicine Emergency Medicine

54. Pediatrics, Dehydration (Follow-up)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvODAxMDEyLXRyZWF0bWVudA== processing > Pediatric Dehydration Treatment & Management Updated: Nov 12, 2018 Author: Alex Koyfman, MD; Chief Editor: Muhammad Waseem, MBBS, MS, FAAP, FACEP, FAHA Share Email Print Feedback Close Sections Sections Pediatric Dehydration Treatment Approach Considerations Address emergent airway, breathing, and circulatory problems first. Obtain intravenous access, and give a 20 mL/kg isotonic fluid bolus (Ringer lactate or normal saline) to children with severe volume depletion. This should (...) dose is 0.25 g/kg IV (2.5 mL/kg of 10% dextrose or 1 mL/kg of 25% dextrose) with reassessment of glucose level after administration of dextrose. Once vital sign abnormalities are corrected, initiate maintenance fluid therapy plus additional fluid to make up for any continued losses. Daily requirements for maintenance fluids can be approximated as follows: If the patient weighs less than 10 kg, give 100 mL/kg/d If the patient weighs less than 20 kg, give 1000 mL/d plus 50 mL/kg/d for each kilogram

2014 eMedicine Emergency Medicine

55. A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

/ IVA 250 mg q12h Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96. Drug: Lumacaftor Plus Ivacaftor Combination Fixed dose combination tablet, oral use Outcome Measures Go to Primary Outcome Measures : Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious (...) categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug was considered treatment-emergent. Part B Treatment Cohort: Number of Participants With Treatment-Emergent AEs and SAEs [ Time Frame: Day 1 up

2013 Clinical Trials

56. A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

of orally administered lumacaftor in combination with ivacaftor in participants aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. The study included a Screening Period (Day -28 through Day -1), a Treatment Period (Day 1 [first dose of study drug] to Week 24 ± 5 days), and a Safety Follow-up Visit (4 weeks ± 7 days after the Week 24 Visit). Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 563 (...) Completion Date : April 2014 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24. Drug: Placebo Matching placebo tablet Experimental: LUM 600 mg qd/IVA 250 mg q12h LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet

2013 Clinical Trials

57. A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

administered lumacaftor in combination with ivacaftor in participants aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. The study included a Screening Period (Day -28 through Day -1), a Treatment Period (Day 1 [first dose of study drug] to Week 24 ± 5 days), and a Safety Follow-up Visit (4 weeks ± 7 days after the Week 24 Visit). Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 559 participants Allocation (...) Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24. Drug: Placebo Matching placebo tablet Experimental: LUM 600 mg qd/IVA 250 mg q12h LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg

2013 Clinical Trials

58. Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children

and laceration repair in an inner city, tertiary care pediatric ED. Random sequence allocation was performed using a computer-generated, random number table by the study research pharmacist. The study participants were grouped according to their age as follows (1) 3-6 years (2) 7-12 years (3) 13-18 years. Children from each age group were assigned in equal numbers to all three ketamine dosing (1 mg/kg, 1.5 mg/kg and 2 mg/kg) groups using random permuted blocks stratified by the pharmacist. All ED staff (...) table for additonal information Responsible Party: Nirupama Kannikeswaran, Associate Professor of Pediatrics and Emergency Medicine, Children's Hospital of Michigan ClinicalTrials.gov Identifier: Other Study ID Numbers: R1-2013-88 First Posted: August 11, 2015 Results First Posted: October 12, 2016 Last Update Posted: October 12, 2016 Last Verified: August 2016 Keywords provided by Nirupama Kannikeswaran, Children's Hospital of Michigan: Procedural sedation ketamine children Additional relevant MeSH

2015 Clinical Trials

59. A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter. Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to 24 Weeks [ Time Frame (...) A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2014 Clinical Trials

60. A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter. Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to 24 Weeks [ Time Frame (...) A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>